Literature DB >> 15765409

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

Boris Julien1, Pascale Grenard, Fatima Teixeira-Clerc, Jeanne Tran Van Nhieu, Liying Li, Meliha Karsak, Andreas Zimmer, Ariane Mallat, Sophie Lotersztajn.   

Abstract

BACKGROUND & AIMS: Hepatic myofibroblasts are central for the development of liver fibrosis associated with chronic liver diseases, and blocking their accumulation may prevent fibrogenesis. Cannabinoids are the active components of marijuana and act via 2 G-protein-coupled receptors, CB1 and CB2. Here, we investigated whether liver fibrogenic cells are a target of cannabinoids.
METHODS: CB2 receptors were characterized in biopsy specimens of normal human liver and active cirrhosis by immunohistochemistry, and in cultures of hepatic stellate cells and hepatic myofibroblasts by reverse-transcription polymerase chain reaction (RT-PCR), immunocytochemistry, and GTPgammaS assays. Functional studies were performed in cultured hepatic myofibroblasts and activated hepatic stellate cells. Carbon tetrachloride-induced liver fibrosis was studied in mice invalidated for CB2 receptors.
RESULTS: In liver biopsy specimens from patients with active cirrhosis of various etiologies, CB2 receptors were expressed in nonparenchymal cells located within and at the edge of fibrous septa in smooth muscle alpha-actin-positive cells. In contrast, CB2 receptors were not detected in normal human liver. CB2 receptors were also detected in cultured hepatic myofibroblasts and in activated hepatic stellate cells. Their activation triggered potent antifibrogenic effects, namely, growth inhibition and apoptosis. Growth inhibition involved cyclooxygenase-2, and apoptosis resulted from oxidative stress. Finally, mice invalidated for CB2 receptors developed enhanced liver fibrosis following chronic carbon tetrachloride treatment as compared with wild-type mice.
CONCLUSIONS: These data constitute the first demonstration that CB2 receptors are highly up-regulated in the cirrhotic liver, predominantly in hepatic fibrogenic cells. Moreover, this study also highlights the antifibrogenic role of CB2 receptors during chronic liver injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765409     DOI: 10.1053/j.gastro.2004.12.050

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  147 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.

Authors:  Amélie Servettaz; Niloufar Kavian; Carole Nicco; Vanessa Deveaux; Christiane Chéreau; Andrew Wang; Andreas Zimmer; Sophie Lotersztajn; Bernard Weill; Frédéric Batteux
Journal:  Am J Pathol       Date:  2010-05-27       Impact factor: 4.307

Review 3.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

Review 4.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

5.  Peripheral cannabinoid receptor, CB2, regulates bone mass.

Authors:  Orr Ofek; Meliha Karsak; Nathalie Leclerc; Meirav Fogel; Baruch Frenkel; Karen Wright; Joseph Tam; Malka Attar-Namdar; Vardit Kram; Esther Shohami; Raphael Mechoulam; Andreas Zimmer; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

Review 6.  Extracellular matrix and liver disease.

Authors:  Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

7.  Cannabinoid receptor 1 is a major mediator of renal fibrosis.

Authors:  Lola Lecru; Christophe Desterke; Stanislas Grassin-Delyle; Christos Chatziantoniou; Sophie Vandermeersch; Aurore Devocelle; Amelia Vernochet; Ninoslav Ivanovski; Catherine Ledent; Sophie Ferlicot; Meriem Dalia; Myriam Saïd; Séverine Beaudreuil; Bernard Charpentier; Aimé Vazquez; Julien Giron-Michel; Bruno Azzarone; Antoine Durrbach; Hélène François
Journal:  Kidney Int       Date:  2015-03-11       Impact factor: 10.612

Review 8.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Opposite effects of cannabinoid CB1 and CB2 receptors on antipsychotic clozapine-induced cardiotoxicity.

Authors:  Liliang Li; Xiaoru Dong; Chunyan Tu; Xiaoqing Li; Zhao Peng; Yiling Zhou; Dingang Zhang; Jieqing Jiang; Allen Burke; Ziqin Zhao; Li Jin; Yan Jiang
Journal:  Br J Pharmacol       Date:  2019-03-04       Impact factor: 8.739

10.  Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.

Authors:  Venkatesh L Hegde; Shweta Hegde; Benjamin F Cravatt; Lorne J Hofseth; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Mol Pharmacol       Date:  2008-04-03       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.